Lenvatinib (off Label)
Lenvatinib + pembrolizumab
Eisai (investigator studies) · Phase 2 · Active, not recruiting · Enrollment 64
| Arm | Reported safety |
|---|---|
| Lenvatinib + pembrolizumab | grade 3 or higher toxicity: 71%, ASCO 2023 (search record) |
A count stays a count. This page does not turn a count into a percent.